2014
DOI: 10.1016/j.jss.2013.11.1104
|View full text |Cite
|
Sign up to set email alerts
|

Thalidomide prolongs survival after experimental musculoskeletal injury, through an effect on mononuclear apoptosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
1
0

Year Published

2015
2015
2018
2018

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 37 publications
(34 reference statements)
1
1
0
Order By: Relevance
“…[23] Thalidomide is known to inhibit TNF-α through expedited degradation of messenger RNA. [24] Our study was coherent with above studies that found increased TNF-α levels. At the same time, it was observed that both etanercept and thalidomide treatment was convenient in decreasing TNF-α levels.…”
Section: Discussionsupporting
confidence: 93%
“…[23] Thalidomide is known to inhibit TNF-α through expedited degradation of messenger RNA. [24] Our study was coherent with above studies that found increased TNF-α levels. At the same time, it was observed that both etanercept and thalidomide treatment was convenient in decreasing TNF-α levels.…”
Section: Discussionsupporting
confidence: 93%
“…In the study by Panousis evaluating thalidomide effect on musculoskeletal injury in an experimental model, thalidomide prolonged the survival of experimental models with musculoskeletal injury by preventing mononuclear apoptosis. Therefore, thalidomide can be used for management of severe traumas [12]. Thalidomide has several adverse effect on the patients with multiple myeloma, but the most common complication is toxic neuropathy.…”
Section: Discussionmentioning
confidence: 99%